DE69400887D1 - Sulphonamid-Derivate - Google Patents

Sulphonamid-Derivate

Info

Publication number
DE69400887D1
DE69400887D1 DE69400887T DE69400887T DE69400887D1 DE 69400887 D1 DE69400887 D1 DE 69400887D1 DE 69400887 T DE69400887 T DE 69400887T DE 69400887 T DE69400887 T DE 69400887T DE 69400887 D1 DE69400887 D1 DE 69400887D1
Authority
DE
Germany
Prior art keywords
cathepsin
sulphonamide derivatives
amyotrophia
calpain
hypercalcemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69400887T
Other languages
English (en)
Other versions
DE69400887T2 (de
Inventor
Ryoichi Ando
Toshiro Sakaki
Chizuko Takahashi
Yoshiyuki Fujimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Application granted granted Critical
Publication of DE69400887D1 publication Critical patent/DE69400887D1/de
Publication of DE69400887T2 publication Critical patent/DE69400887T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DE69400887T 1993-04-28 1994-04-21 Sulphonamid-Derivate Expired - Fee Related DE69400887T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10278293 1993-04-28

Publications (2)

Publication Number Publication Date
DE69400887D1 true DE69400887D1 (de) 1996-12-19
DE69400887T2 DE69400887T2 (de) 1997-05-22

Family

ID=14336717

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69400887T Expired - Fee Related DE69400887T2 (de) 1993-04-28 1994-04-21 Sulphonamid-Derivate

Country Status (10)

Country Link
US (1) US5506243A (de)
EP (1) EP0623627B1 (de)
JP (1) JP3599287B2 (de)
AT (1) ATE145214T1 (de)
CA (1) CA2121523C (de)
DE (1) DE69400887T2 (de)
DK (1) DK0623627T3 (de)
ES (1) ES2096370T3 (de)
GR (1) GR3022524T3 (de)
TW (1) TW261608B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5872101A (en) * 1995-01-06 1999-02-16 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
ATE230389T1 (de) * 1995-10-25 2003-01-15 Senju Pharma Co Angiogenese inhibitoren
EP0928786B1 (de) * 1995-10-25 2003-01-02 Senju Pharmaceutical Co., Ltd. Angiogenese Inhibitoren
US6214800B1 (en) 1995-10-25 2001-04-10 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
AU714324B2 (en) * 1995-11-28 2000-01-06 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
WO1998003191A1 (en) * 1996-07-19 1998-01-29 Neurotrauma Therapeutics, Inc. Calpain inhibitors for the treatment of cerebral ischemia, spinal cord injury or stroke
AU3805497A (en) * 1996-07-19 1998-02-10 Neurotrauma Therapeutics, Inc. Calpain inhibitors for the treatment of traumatic brain injury
US6303579B1 (en) 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
JP2002515051A (ja) 1996-12-31 2002-05-21 ジーピーアイ エヌアイエル ホールディングス インコーポレイテッド ヘテロ環式チオエステルのｎ−結合スルホンアミド
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
ID27083A (id) 1998-03-05 2001-02-22 Senju Pharma Co Komposisi farmasi untuk pencegahan dan pengobatan penyakit-penyakit yang behubungan dengan sitopati jaringan okuler fundus
US7459473B2 (en) 1998-06-03 2008-12-02 Glia Med, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
MXPA02006134A (es) 1999-12-21 2002-12-13 Guilford Pharm Inc Compuestos derivados de hidantoina, composiciones farmaceuticas y metodos de uso de los mismos.
EP1254901A4 (de) * 2000-01-26 2003-03-05 Ono Pharmaceutical Co Stickstoffhältige, 5-gliedrige, zyklische verbindungen und diese als wirkstoffe enthaltende medikamente
WO2002010768A2 (en) * 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
US7572833B2 (en) * 2000-10-26 2009-08-11 Senju Pharmaceutical Co., Ltd. Drug composition comprising dipeptidyl aldehyde derivative
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
JP4549851B2 (ja) * 2002-07-22 2010-09-22 千寿製薬株式会社 新規α−ケトアミド誘導体およびその用途
JP2006526657A (ja) * 2003-06-04 2006-11-24 アクシス ファーマシューティカルズ システインプロテアーゼ阻害剤としてのアミジノ化合物
WO2005028429A2 (en) 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
JP5154944B2 (ja) 2004-12-02 2013-02-27 ビロベイ，インコーポレイティド システインプロテアーゼインヒビターとしてのスルホンアミド含有化合物
US7488848B2 (en) 2005-03-21 2009-02-10 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
JP5215167B2 (ja) 2005-03-22 2013-06-19 ビロベイ，インコーポレイティド システインプロテアーゼ阻害剤としてのスルホニル基含有化合物
WO2008045017A2 (en) * 2005-06-22 2008-04-17 Diamond Scott L Sars and ebola inhibitors and use thereof, and methods for their discovery
KR101486763B1 (ko) 2006-10-04 2015-01-28 비로베이, 인코포레이티드 시스테인 프로테아제 억제제로서의 디­플루오로 함유 화합물
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
EP3755352A4 (de) * 2018-02-20 2021-12-22 Edgewise Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von bewegungserkrankungen
JP7355777B2 (ja) 2021-03-31 2023-10-03 本田技研工業株式会社 切削工具
WO2024018245A1 (en) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of calpain inhibitors for the treatment of the diabetic kidney disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient

Also Published As

Publication number Publication date
EP0623627A1 (de) 1994-11-09
GR3022524T3 (en) 1997-05-31
ATE145214T1 (de) 1996-11-15
CA2121523A1 (en) 1994-10-29
JP3599287B2 (ja) 2004-12-08
TW261608B (de) 1995-11-01
DE69400887T2 (de) 1997-05-22
ES2096370T3 (es) 1997-03-01
DK0623627T3 (da) 1997-04-28
CA2121523C (en) 2006-06-20
JPH0748340A (ja) 1995-02-21
EP0623627B1 (de) 1996-11-13
US5506243A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
DE69400887D1 (de) Sulphonamid-Derivate
ES2117088T3 (es) Derivados de aminocetonas.
CA2217737A1 (en) Thf-containing sulfonamide inhibitors of aspartyl protease
EP0885887A3 (de) Sulfonamide Inhibitore von HIV-Aspartyl Protease
NL300283I1 (nl) Alfa- en bèta-aminozuur-hydroxyethylamino-sulfonamiden die toepasbaar zijn als retrovirale-prothease-remmers.
AP9600827A0 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease.
EP0739338A4 (de) Neue sterin-protease inhibitoren: isothiazolidin-3-on-1,1-dioxid und 3-oxo-1,2,5-thiadiazolidin 1,1-dioxid
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
DE60214392D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
PT1052250E (pt) Inibidores de protease retroviral sulfonilalcanoilamino hidroxietilamino sulfonamidas
DE69624346D1 (de) Verbindung der struktur aminosäure-hydroxyethylamino-sulfonamide als inhibitoren der retroviralen protease
HUP0203130A2 (hu) Hexahidrofuro[2,3-b]furán-3-il-N-{3-(1,3-benzodioxol-5-il-szulfonil)-(izobutil)-amino-1-benzil-2-(hidroxi-propil)}-karbamát mint retrovírus-proteáz-gátló
NO952207D0 (no) Anvendelse av 2-amino-6-A-propylamino-4,5,6,7-tetrahydrobenzotiazol (pramipexol) som et antidepresivt legemiddel
DE60132177D1 (en) Aminosäure-derivate als hiv aspartyl-protease-inhibitoren
DZ3008A1 (fr) Inhibiteurs de l'aspartyle protéase.
NO308897B1 (no) Benzotiazin-dioksyder som endotelin-antagonister, fremgangsmÕter for fremstilling derav, farmasøytiske preparater omfattende forbindelsene, samt anvendelse av forbindelsene
NO974322L (no) DNA som koder for human papillomvirus type 18
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
EA200000016A1 (ru) Гидроксициклопентанон
NO942983D0 (no) Farmasöytiske sammensetninger
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
DK0642574T3 (da) Detergentsammensætninger
EA199900683A1 (ru) Тетрагидрофураны
ATE359218T1 (de) Verriegelungsmechanismus für einen behälter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee